| Autor: |
Yumin Zhou, Fan Wu, Zhe Shi, Jie Cao, Jia Tian, Weimin Yao, Liping Wei, Fenglei Li, Shan Cai, Yao Shen, Zanfeng Wang, Huilan Zhang, Yanfan Chen, Yingyun Fu, Zhiyi He, Chun Chang, Yongliang Jiang, Shujing Chen, Changli Yang, Shuqing Yu, Heshen Tian, Qijian Cheng, Ziwen Zhao, Yinghua Ying, Yong Zhou, Shengming Liu, Zhishan Deng, Peiyu Huang, Yunzhen Zhang, Xiangwen Luo, Haiyan Zhao, Jianping Gui, Weiguang Lai, Guoping Hu, Cong Liu, Ling Su, Zhiguang Liu, Jianhui Huang, Dongxing Zhao, Nanshan Zhong, Pixin Ran, On behalf of China N-acetylcysteine in Mild-to-moderate COPD Study Group |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2041-1723 |
| DOI: |
10.1038/s41467-024-51079-1 |
| Popis: |
Abstract Evidence for the treatment of patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) is limited. The efficacy of N-acetylcysteine (an antioxidant and mucolytic agent) for patients with mild-to-moderate COPD is uncertain. In this multicentre, randomised, double-blind, placebo-controlled trial, we randomly assigned 968 patients with mild-to-moderate COPD to treatment with N-acetylcysteine (600 mg, twice daily) or matched placebo for two years. Eligible participants were 40-80 years of age and had mild-to-moderate COPD (forced expiratory volume in 1 second [FEV1] to forced vital capacity ratio |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink